BioXcel Therapeutics (BTAI) Debt to Equity (2022 - 2025)
Historic Debt to Equity for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$1.23.
- BioXcel Therapeutics' Debt to Equity fell 62.46% to -$1.23 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.23, marking a year-over-year decrease of 62.46%. This contributed to the annual value of -$1.1 for FY2024, which is 3815.22% up from last year.
- According to the latest figures from Q3 2025, BioXcel Therapeutics' Debt to Equity is -$1.23, which was down 62.46% from -$1.01 recorded in Q2 2025.
- BioXcel Therapeutics' Debt to Equity's 5-year high stood at $16.66 during Q2 2023, with a 5-year trough of -$2.46 in Q3 2023.
- For the 4-year period, BioXcel Therapeutics' Debt to Equity averaged around $0.53, with its median value being -$1.1 (2024).
- Over the last 5 years, BioXcel Therapeutics' Debt to Equity had its largest YoY gain of 62375141.7% in 2023, and its largest YoY loss of 43943.53% in 2023.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Debt to Equity stood at $1.22 in 2022, then plummeted by 246.22% to -$1.78 in 2023, then skyrocketed by 38.15% to -$1.1 in 2024, then decreased by 11.46% to -$1.23 in 2025.
- Its Debt to Equity was -$1.23 in Q3 2025, compared to -$1.01 in Q2 2025 and -$1.17 in Q1 2025.